<DOC>
	<DOC>NCT02137928</DOC>
	<brief_summary>This study will evaluate the clinical efficacy of periocular injections of carboplatin together with chemotherapy in the treatment of Retinoblastoma as compared to chemotherapy alone.</brief_summary>
	<brief_title>Carboplatin Periocular Injection for Retinoblastoma</brief_title>
	<detailed_description>This study will be a phase Ⅲ open label interventional case series. Patients with retinoblastoma will be randomized to receive chemotherapy with or without periocular injections of carboplatin at a dose of 20mg/2 ml. Patients will receive carboplatin periocular on a monthly basis for a total duration of therapy of 6 months. Patients will be followed for 24 months .</detailed_description>
	<mesh_term>Retinoblastoma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Ability to provide written informed consent and comply with study assessments for the full duration of the study. linical diagnosis of retinoblastoma, Stage 0 or Ⅱ base on International Retinoblastoma Staging System. Any previous disease in the study eye. Previous participation in any studies of investigational drugs within 1 month preceding Day 0 (excluding vitamins and minerals). History of chemical intervention for retinoblastoma in the study eye.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Retinoblastoma</keyword>
	<keyword>carboplatin</keyword>
</DOC>